MELISSA RUARK: Open Payments
NPI 1659722700 · GAINESVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$634 in 30 payments from 14 companies in 2025. Trend: 2023 $827 · 2024 $871 · 2025 $634
Food & beverage: $634
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $175 |
| Novartis Pharmaceuticals Corporation | 9 | $144 |
| Actelion Pharmaceuticals US, Inc. | 3 | $61 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Amgen Inc. | 2 | $38 |
| Edwards Lifesciences Corporation | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| ABIOMED | 1 | $19 |
Products named: VYNDAQEL, LEQVIO, OPSUMIT, VERQUVO, REPATHA, SAPIEN 3 Ultra RESILIA, AMVUTTRA, JARDIANCE.
Industry payments across GA — which companies pay providers there.
